Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...

Have you assessed how the international operations of Eli Lilly (LLY) performed in the quarter ended March 2025? For this drugmaker, possessing an expansive global footprint, parsing the trends of ...

Highlights,Eli Lilly posts revenue growth supported by healthcare innovation.,Sector trends mirror broader momentum within the S&P 500.,Commercial focus remains aligned with index ...

Eli Lilly (NYSE:LLY) recently announced leadership transitions, including new roles for Ilya Yuffa, Patrik Jonsson, and ...

Eli Lilly (NYSE: NYSE:LLY) is set to report its first-quarter earnings on Thursday, May 1st, before the market opens. Street Expectations Analysts expect the drugmaker to earn $3.46 (+34.1% Y/Y) on ...

A consultancy’s new ranking of drug company R&D shows Eli Lilly has risen to the top of the drug development heap, while ...

Eli Lilly's Zepbound loses CVS coverage to Wegovy, prompting analyst debate on pricing pressures and long-term obesity market ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

Despite these headline-grabbing results, Eli Lilly's stock movement remained flat over the last month, aligning with broader market trends, which also showed little change. The company's ...

Eli Lilly (NYSE:LLY) recently announced the impressive results of its SURMOUNT-5 trial, highlighting Zepbound's efficacy over ...